{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:56:35Z","timestamp":1790574995928,"version":"4.1.0"},"reference-count":119,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04572-6","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:26:21Z","timestamp":1790573181000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Applications of circulating tumor DNA in unresectable and advanced non-small cell lung cancer immunotherapy: from stratification to therapeutic guidance"],"prefix":"10.1007","author":[{"given":"Linxiang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suli","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxiu","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenrong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2533-7147","authenticated-orcid":false,"given":"Tao","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"4572_CR1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2022.40.16_suppl.e21097","author":"W Barliz","year":"2022","unstructured":"Barliz W, Yasmin L, Ofer M, Ido W. The use of medical cannabis concomitantly with immune-check point inhibitors (ICI) in non-small cell lung cancer (NSCLC): a sigh of relief? J Clin Oncol. 2022. https:\/\/doi.org\/10.1200\/jco.2022.40.16_suppl.e21097.","journal-title":"J Clin Oncol"},{"issue":"19","key":"4572_CR2","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823\u201333.","journal-title":"N Engl J Med"},{"issue":"21","key":"4572_CR3","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","volume":"381","author":"MD Hellmann","year":"2019","unstructured":"Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim S-W, Carcereny Costa E, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019;381(21):2020\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1910231.","journal-title":"N Engl J Med"},{"issue":"20","key":"4572_CR4","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377(20):1919\u201329. https:\/\/doi.org\/10.1056\/NEJMoa1709937.","journal-title":"N Engl J Med"},{"issue":"20","key":"4572_CR5","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1056\/NEJMe1711430","volume":"377","author":"NA Rizvi","year":"2017","unstructured":"Rizvi NA, Peters S. Immunotherapy for unresectable stage III non-small-cell lung cancer. N Engl J Med. 2017;377(20):1986\u20138. https:\/\/doi.org\/10.1056\/NEJMe1711430.","journal-title":"N Engl J Med"},{"issue":"2","key":"4572_CR6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jtho.2022.10.003","volume":"18","author":"N Girard","year":"2023","unstructured":"Girard N, Bar J, Garrido P, Garassino MC, McDonald F, Mornex F, et al. Treatment characteristics and real-world progression-free survival in patients with unresectable stage III NSCLC who received durvalumab after chemoradiotherapy: findings from the PACIFIC-R study. J Thorac Oncol. 2023;18(2):181\u201393. https:\/\/doi.org\/10.1016\/j.jtho.2022.10.003.","journal-title":"J Thorac Oncol"},{"issue":"3","key":"4572_CR7","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S2213-2600(20)30365-9","volume":"9","author":"C Zhou","year":"2021","unstructured":"Zhou C, Chen G, Huang Y, Zhou J, Lin L, Feng J, et al. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. Lancet Respir Med. 2021;9(3):305\u201314. https:\/\/doi.org\/10.1016\/S2213-2600(20)30365-9.","journal-title":"Lancet Respir Med"},{"issue":"12","key":"4572_CR8","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1200\/JCO.21.01308","volume":"40","author":"DR Spigel","year":"2022","unstructured":"Spigel DR, Faivre-Finn C, Gray JE, Vicente D, Planchard D, Paz-Ares L, et al. Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J Clin Oncol. 2022;40(12):1301\u201311. https:\/\/doi.org\/10.1200\/JCO.21.01308.","journal-title":"J Clin Oncol"},{"issue":"10","key":"4572_CR9","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1016\/j.jtho.2021.05.001","volume":"16","author":"RS Herbst","year":"2021","unstructured":"Herbst RS, Garon EB, Kim D-W, Cho BC, Gervais R, Perez-Gracia JL, et al. Five year survival update from KEYNOTE-010: pembrolizumab versus docetaxel for previously treated, programmed death-ligand 1-positive advanced NSCLC. J Thorac Oncol. 2021;16(10):1718\u201332. https:\/\/doi.org\/10.1016\/j.jtho.2021.05.001.","journal-title":"J Thorac Oncol"},{"issue":"3","key":"4572_CR10","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1200\/JCO.22.00727","volume":"41","author":"Z Wang","year":"2023","unstructured":"Wang Z, Wu L, Li B, Cheng Y, Li X, Wang X, et al. Toripalimab plus chemotherapy for patients with treatment-naive advanced non-small-cell lung cancer: a multicenter randomized phase III trial (CHOICE-01). J Clin Oncol. 2023;41(3):651\u201363. https:\/\/doi.org\/10.1200\/JCO.22.00727.","journal-title":"J Clin Oncol"},{"issue":"11","key":"4572_CR11","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1200\/JCO.23.00580","volume":"42","author":"B Ricciuti","year":"2024","unstructured":"Ricciuti B, Lamberti G, Puchala SR, Mahadevan NR, Lin J-R, Alessi JV, et al. Genomic and immunophenotypic landscape of acquired resistance to PD-(L)1 blockade in non-small-cell lung cancer. J Clin Oncol. 2024;42(11):1311\u201321. https:\/\/doi.org\/10.1200\/JCO.23.00580.","journal-title":"J Clin Oncol"},{"issue":"6","key":"4572_CR12","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1200\/jco.21.01497","volume":"40","author":"M Reck","year":"2022","unstructured":"Reck M, Remon J, Hellmann MD. First-line immunotherapy for non-small-cell lung cancer. J Clin Oncol. 2022;40(6):586\u201397. https:\/\/doi.org\/10.1200\/jco.21.01497.","journal-title":"J Clin Oncol"},{"key":"4572_CR13","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_321483","author":"MD Shields","year":"2021","unstructured":"Shields MD, Marin-Acevedo JA, Pellini B. Immunotherapy for advanced non-small cell lung cancer: a decade of progress. Am Soc Clin Oncol Educ Book. 2021. https:\/\/doi.org\/10.1200\/EDBK_321483.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"4572_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001343","author":"P Vaidya","year":"2020","unstructured":"Vaidya P, Bera K, Patil PD, Gupta A, Jain P, Alilou M, et al. Novel, non-invasive imaging approach to identify patients with advanced non-small cell lung cancer at risk of hyperprogressive disease with immune checkpoint blockade. J Immunother Cancer. 2020. https:\/\/doi.org\/10.1136\/jitc-2020-001343.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"4572_CR15","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.annonc.2022.09.163","volume":"34","author":"ZR Reichert","year":"2023","unstructured":"Reichert ZR, Morgan TM, Li G, Castellanos E, Snow T, Dall\u2019Olio FG, et al. Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study. Ann Oncol. 2023;34(1):111\u201320. https:\/\/doi.org\/10.1016\/j.annonc.2022.09.163.","journal-title":"Ann Oncol"},{"issue":"4","key":"4572_CR16","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.annonc.2023.01.008","volume":"34","author":"A Bayle","year":"2023","unstructured":"Bayle A, Belcaid L, Aldea M, Vasseur D, Peyraud F, Nicotra C, et al. Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study. Ann Oncol. 2023;34(4):389\u201396. https:\/\/doi.org\/10.1016\/j.annonc.2023.01.008.","journal-title":"Ann Oncol"},{"key":"4572_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3519","author":"AM Newman","year":"2014","unstructured":"Newman AM, Bratman SV, To J, Wynne JF, Eclov NCW, Modlin LA, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014. https:\/\/doi.org\/10.1038\/nm.3519.","journal-title":"Nat Med"},{"issue":"12","key":"4572_CR18","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1158\/2159-8290.CD-21-0634","volume":"11","author":"EJ Moding","year":"2021","unstructured":"Moding EJ, Nabet BY, Alizadeh AA, Diehn M. Detecting liquid remnants of solid tumors: circulating tumor DNA minimal residual disease. Cancer Discov. 2021;11(12):2968\u201386. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0634.","journal-title":"Cancer Discov"},{"issue":"12","key":"4572_CR19","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1158\/2159-8290.CD-17-0716","volume":"7","author":"AA Chaudhuri","year":"2017","unstructured":"Chaudhuri AA, Chabon JJ, Lovejoy AF, Newman AM, Stehr H, Azad TD, et al. Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. Cancer Discov. 2017;7(12):1394\u2013403. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0716.","journal-title":"Cancer Discov"},{"key":"4572_CR20","unstructured":"Mandel P, Metais P. Les acides nucl\u00e9iques du plasma sanguin chez l'homme. C R Seances Soc Biol Fil. 1948;142(3\u20134):241\u20133. PMID: 18875018."},{"issue":"18","key":"4572_CR21","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1056\/NEJMra1706174","volume":"379","author":"RB Corcoran","year":"2018","unstructured":"Corcoran RB, Chabner BA. Application of cell-free DNA analysis to cancer treatment. N Engl J Med. 2018;379(18):1754\u201365. https:\/\/doi.org\/10.1056\/NEJMra1706174.","journal-title":"N Engl J Med"},{"issue":"8","key":"4572_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/gm474","volume":"5","author":"E Kidess","year":"2013","unstructured":"Kidess E, Jeffrey SS. Circulating tumor cells versus tumor-derived cell-free DNA: rivals or partners in cancer care in the era of single-cell analysis? Genome Med. 2013;5(8):70. https:\/\/doi.org\/10.1186\/gm474.","journal-title":"Genome Med"},{"issue":"4","key":"4572_CR23","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/nrc.2017.7","volume":"17","author":"JCM Wan","year":"2017","unstructured":"Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17(4):223\u201338. https:\/\/doi.org\/10.1038\/nrc.2017.7.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"4572_CR24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12943-022-01710-w","volume":"22","author":"P Stejskal","year":"2023","unstructured":"Stejskal P, Goodarzi H, Srovnal J, Hajd\u00fach M, van \u2018t Veer LJ, Magbanua MJM. Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance. Mol Cancer. 2023;22(1):15. https:\/\/doi.org\/10.1186\/s12943-022-01710-w.","journal-title":"Mol Cancer"},{"issue":"5","key":"4572_CR25","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.annonc.2022.02.007","volume":"33","author":"D Gale","year":"2022","unstructured":"Gale D, Heider K, Ruiz-Valdepenas A, Hackinger S, Perry M, Marsico G, et al. Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer. Ann Oncol. 2022;33(5):500\u201310. https:\/\/doi.org\/10.1016\/j.annonc.2022.02.007.","journal-title":"Ann Oncol"},{"issue":"11","key":"4572_CR26","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/s41568-024-00742-2","volume":"24","author":"AJ Medford","year":"2024","unstructured":"Medford AJ, Carmeli AB, Ritchie A, Wagle N, Garraway L, Lander ES, et al. A standing platform for cancer drug development using ctDNA-based evidence of recurrence. Nat Rev Cancer. 2024;24(11):810\u201321. https:\/\/doi.org\/10.1038\/s41568-024-00742-2.","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"4572_CR27","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1038\/s41591-024-03254-6","volume":"30","author":"Y Nakamura","year":"2024","unstructured":"Nakamura Y, Watanabe J, Akazawa N, Hirata K, Kataoka K, Yokota M, et al. CtDNA-based molecular residual disease and survival in resectable colorectal cancer. Nat Med. 2024;30(11):3272\u201383. https:\/\/doi.org\/10.1038\/s41591-024-03254-6.","journal-title":"Nat Med"},{"issue":"10","key":"4572_CR28","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1038\/s41591-023-02598-9","volume":"29","author":"V Anagnostou","year":"2023","unstructured":"Anagnostou V, Ho C, Nicholas G, Juergens RA, Sacher A, Fung AS, et al. CtDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results. Nat Med. 2023;29(10):2559\u201369. https:\/\/doi.org\/10.1038\/s41591-023-02598-9.","journal-title":"Nat Med"},{"key":"4572_CR29","doi-asserted-by":"publisher","DOI":"10.1172\/jci154941","author":"DK Dang","year":"2022","unstructured":"Dang DK, Park BH. Circulating tumor DNA: current challenges for clinical utility. J Clin Investig. 2022. https:\/\/doi.org\/10.1172\/jci154941.","journal-title":"J Clin Investig"},{"issue":"2","key":"4572_CR30","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/humu.1380020209","volume":"2","author":"S Takeda","year":"1993","unstructured":"Takeda S, Ichii S, Nakamura Y. Detection of K-ras mutation in sputum by mutant-allele-specific amplification (MASA). Hum Mutat. 1993;2(2):112\u20137.","journal-title":"Hum Mutat"},{"key":"4572_CR31","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.canlet.2017.06.008","volume":"403","author":"Z Liang","year":"2017","unstructured":"Liang Z, Cheng Y, Chen Y, Hu Y, Liu W-P, Lu Y, et al. EGFR T790M ctDNA testing platforms and their role as companion diagnostics: correlation with clinical outcomes to EGFR-TKIs. Cancer Lett. 2017;403:186\u201394. https:\/\/doi.org\/10.1016\/j.canlet.2017.06.008.","journal-title":"Cancer Lett"},{"issue":"16","key":"4572_CR32","doi-asserted-by":"publisher","first-page":"9236","DOI":"10.1073\/pnas.96.16.9236","volume":"96","author":"B Vogelstein","year":"1999","unstructured":"Vogelstein B, Kinzler KW. Digital PCR. Proc Natl Acad Sci USA. 1999;96(16):9236\u201341.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4572_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2023.117239","author":"S Crucitta","year":"2023","unstructured":"Crucitta S, Ruglioni M, Novi C, Manganiello M, Arici R, Petrini I, et al. Comparison of digital PCR systems for the analysis of liquid biopsy samples of patients affected by lung and colorectal cancer. Clin Chim Acta. 2023. https:\/\/doi.org\/10.1016\/j.cca.2023.117239.","journal-title":"Clin Chim Acta"},{"key":"4572_CR34","doi-asserted-by":"publisher","DOI":"10.1080\/14737159.2018.1400384","author":"M Postel","year":"2018","unstructured":"Postel M, Roosen A, Laurent-Puig P, Taly V, Wang-Renault S-F. Droplet-based digital PCR and next generation sequencing for monitoring circulating tumor DNA: a cancer diagnostic perspective. Expert Rev Mol Diagn. 2018. https:\/\/doi.org\/10.1080\/14737159.2018.1400384.","journal-title":"Expert Rev Mol Diagn"},{"issue":"2","key":"4572_CR35","doi-asserted-by":"publisher","first-page":"351","DOI":"10.4143\/crt.2022.1026","volume":"55","author":"H Kim","year":"2023","unstructured":"Kim H, Park KU. Clinical circulating tumor DNA testing for precision oncology. Cancer Res Treat. 2023;55(2):351\u201366. https:\/\/doi.org\/10.4143\/crt.2022.1026.","journal-title":"Cancer Res Treat"},{"issue":"2","key":"4572_CR36","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s11523-019-00623-x","volume":"14","author":"A Buder","year":"2019","unstructured":"Buder A, Setinek U, Hochmair MJ, Schwab S, Kirchbacher K, Keck A, et al. EGFR mutations in cell-free plasma DNA from patients with advanced lung adenocarcinoma: improved detection by droplet digital PCR. Target Oncol. 2019;14(2):197\u2013203. https:\/\/doi.org\/10.1007\/s11523-019-00623-x.","journal-title":"Target Oncol"},{"issue":"3","key":"4572_CR37","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.lungcan.2015.10.004","volume":"90","author":"KS Thress","year":"2015","unstructured":"Thress KS, Brant R, Carr TH, Dearden S, Jenkins S, Brown H, et al. EGFR mutation detection in ctDNA from NSCLC patient plasma: a cross-platform comparison of leading technologies to support the clinical development of AZD9291. Lung Cancer. 2015;90(3):509\u201315. https:\/\/doi.org\/10.1016\/j.lungcan.2015.10.004.","journal-title":"Lung Cancer"},{"key":"4572_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102595","author":"R T\u00e9bar-Mart\u00ednez","year":"2023","unstructured":"T\u00e9bar-Mart\u00ednez R, Mart\u00edn-Arana J, Gimeno-Valiente F, Tarazona N, Rentero-Garrido P, Cervantes A. Strategies for improving detection of circulating tumor DNA using next generation sequencing. Cancer Treat Rev. 2023. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102595.","journal-title":"Cancer Treat Rev"},{"key":"4572_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/cells11121901","author":"D Vasseur","year":"2022","unstructured":"Vasseur D, Sassi H, Bayle A, Tagliamento M, Besse B, Marzac C, et al. Next-generation sequencing on circulating tumor DNA in advanced solid cancer: swiss army knife for the molecular tumor board? A review of the literature focused on FDA approved test. Cells. 2022. https:\/\/doi.org\/10.3390\/cells11121901.","journal-title":"Cells"},{"key":"4572_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14194954","author":"E Zografos","year":"2022","unstructured":"Zografos E, Dimitrakopoulos F-I, Koutras A. Prognostic value of circulating tumor DNA (ctDNA) in oncogene-driven NSCLC: current knowledge and future perspectives. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14194954.","journal-title":"Cancers (Basel)"},{"issue":"11","key":"4572_CR41","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1093\/annonc\/mdz390","volume":"30","author":"N Tarazona","year":"2019","unstructured":"Tarazona N, Gimeno-Valiente F, Gambardella V, Zu\u00f1iga S, Rentero-Garrido P, Huerta M, et al. Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer. Ann Oncol. 2019;30(11):1804\u201312. https:\/\/doi.org\/10.1093\/annonc\/mdz390.","journal-title":"Ann Oncol"},{"key":"4572_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/life11090890","author":"C Lin","year":"2021","unstructured":"Lin C, Liu X, Zheng B, Ke R, Tzeng C-M. Liquid biopsy, ctDNA diagnosis through NGS. Life. 2021. https:\/\/doi.org\/10.3390\/life11090890.","journal-title":"Life"},{"issue":"5","key":"4572_CR43","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s40291-024-00725-x","volume":"28","author":"C Chen","year":"2024","unstructured":"Chen C, Douglas MP, Ragavan MV, Phillips KA, Jansen JP. Clinical validity and utility of circulating tumor DNA (ctDNA) testing in advanced non-small cell lung cancer (aNSCLC): a systematic literature review and meta-analysis. Mol Diagn Ther. 2024;28(5):525\u201336. https:\/\/doi.org\/10.1007\/s40291-024-00725-x.","journal-title":"Mol Diagn Ther"},{"key":"4572_CR44","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan2415","author":"J Phallen","year":"2017","unstructured":"Phallen J, Sausen M, Adleff V, Leal A, Hruban C, White J, et al. Direct detection of early-stage cancers using circulating tumor DNA. Sci Transl Med. 2017. https:\/\/doi.org\/10.1126\/scitranslmed.aan2415.","journal-title":"Sci Transl Med"},{"issue":"23","key":"4572_CR45","doi-asserted-by":"publisher","first-page":"9530","DOI":"10.1073\/pnas.1105422108","volume":"108","author":"I Kinde","year":"2011","unstructured":"Kinde I, Wu J, Papadopoulos N, Kinzler KW, Vogelstein B. Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci USA. 2011;108(23):9530\u20135. https:\/\/doi.org\/10.1073\/pnas.1105422108.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4572_CR46","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aax7392","author":"BR McDonald","year":"2019","unstructured":"McDonald BR, Contente-Cuomo T, Sammut S-J, Odenheimer-Bergman A, Ernst B, Perdigones N, et al. Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer. Sci Transl Med. 2019. https:\/\/doi.org\/10.1126\/scitranslmed.aax7392.","journal-title":"Sci Transl Med"},{"issue":"6","key":"4572_CR47","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1158\/0008-5472.CAN-19-0231","volume":"79","author":"T Zou","year":"2019","unstructured":"Zou T, Meyerson M. Circulating tumor DNA provides a sneak peek into treatment responses in non-small cell lung cancer. Cancer Res. 2019;79(6):1038\u201340. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-0231.","journal-title":"Cancer Res"},{"issue":"8","key":"4572_CR48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0161012","volume":"11","author":"S Dietz","year":"2016","unstructured":"Dietz S, Schirmer U, Merc\u00e9 C, von Bubnoff N, Dahl E, Meister M, et al. Low input whole-exome sequencing to determine the representation of the tumor exome in circulating DNA of non-small cell lung cancer patients. PLoS ONE. 2016;11(8):e0161012. https:\/\/doi.org\/10.1371\/journal.pone.0161012.","journal-title":"PLoS ONE"},{"issue":"7447","key":"4572_CR49","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature12065","volume":"497","author":"M Murtaza","year":"2013","unstructured":"Murtaza M, Dawson S-J, Tsui DWY, Gale D, Forshew T, Piskorz AM, et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature. 2013;497(7447):108\u201312. https:\/\/doi.org\/10.1038\/nature12065.","journal-title":"Nature"},{"issue":"9","key":"4572_CR50","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.tig.2018.05.008","volume":"34","author":"EL van Dijk","year":"2018","unstructured":"van Dijk EL, Jaszczyszyn Y, Naquin D, Thermes C. The third revolution in sequencing technology. Trends Genet. 2018;34(9):666\u201381. https:\/\/doi.org\/10.1016\/j.tig.2018.05.008.","journal-title":"Trends Genet"},{"issue":"1","key":"4572_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-020-1935-5","volume":"21","author":"SL Amarasinghe","year":"2020","unstructured":"Amarasinghe SL, Su S, Dong X, Zappia L, Ritchie ME, Gouil Q. Opportunities and challenges in long-read sequencing data analysis. Genome Biol. 2020;21(1):30. https:\/\/doi.org\/10.1186\/s13059-020-1935-5.","journal-title":"Genome Biol"},{"issue":"5","key":"4572_CR52","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s40291-023-00661-2","volume":"27","author":"SCY Yu","year":"2023","unstructured":"Yu SCY, Choy LYL, Lo YMD. \u2018Longing\u2019 for the next generation of liquid biopsy: the diagnostic potential of long cell-free DNA in oncology and prenatal testing. Mol Diagn Ther. 2023;27(5):563\u201371. https:\/\/doi.org\/10.1007\/s40291-023-00661-2.","journal-title":"Mol Diagn Ther"},{"issue":"12","key":"4572_CR53","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202217282","volume":"15","author":"Y van der Pol","year":"2023","unstructured":"van der Pol Y, Tantyo NA, Evander N, Hentschel AE, Wever BM, Ramaker J, et al. Real-time analysis of the cancer genome and fragmentome from plasma and urine cell-free DNA using nanopore sequencing. EMBO Mol Med. 2023;15(12):EMMM202217282. https:\/\/doi.org\/10.15252\/emmm.202217282.","journal-title":"EMBO Mol Med"},{"issue":"9","key":"4572_CR54","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1101\/gr.261941.120","volume":"30","author":"Y Sakamoto","year":"2020","unstructured":"Sakamoto Y, Xu L, Seki M, Yokoyama TT, Kasahara M, Kashima Y, et al. Long-read sequencing for non-small-cell lung cancer genomes. Genome Res. 2020;30(9):1243\u201357. https:\/\/doi.org\/10.1101\/gr.261941.120.","journal-title":"Genome Res"},{"issue":"1","key":"4572_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41525-021-00272-y","volume":"6","author":"A Marcozzi","year":"2021","unstructured":"Marcozzi A, Jager M, Elferink M, Straver R, van Ginkel JH, Peltenburg B, et al. Accurate detection of circulating tumor DNA using nanopore consensus sequencing. NPJ Genom Med. 2021;6(1):106. https:\/\/doi.org\/10.1038\/s41525-021-00272-y.","journal-title":"NPJ Genom Med"},{"key":"4572_CR56","doi-asserted-by":"publisher","DOI":"10.1093\/gigascience\/giaf139","author":"I Ivankovi\u0107","year":"2025","unstructured":"Ivankovi\u0107 I, Bal\u00e1zs Z, Gitchev T, Trottet C, Moldovan N, Bahce I, et al. The effects of bioinformatics preprocessing on cell-free DNA fragment analysis. GigaScience. 2025. https:\/\/doi.org\/10.1093\/gigascience\/giaf139.","journal-title":"GigaScience"},{"key":"4572_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.102085","volume":"49","author":"AS Sirajee","year":"2024","unstructured":"Sirajee AS, Kabiraj D, De S. Cell-free nucleic acid fragmentomics: a non-invasive window into cellular epigenomes. Transl Oncol. 2024;49:102085. https:\/\/doi.org\/10.1016\/j.tranon.2024.102085.","journal-title":"Transl Oncol"},{"key":"4572_CR58","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.766","author":"L Li","year":"2024","unstructured":"Li L, Sun Y. Circulating tumor DNA methylation detection as biomarker and its application in tumor liquid biopsy: advances and challenges. MedComm. 2024. https:\/\/doi.org\/10.1002\/mco2.766.","journal-title":"MedComm"},{"key":"4572_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55428-y","author":"DV Vavoulis","year":"2025","unstructured":"Vavoulis DV, Cutts A, Thota N, Brown J, Sugar R, Rueda A, et al. Multimodal cell-free DNA whole-genome TAPS is sensitive and reveals specific cancer signals. Nat Commun. 2025. https:\/\/doi.org\/10.1038\/s41467-024-55428-y.","journal-title":"Nat Commun"},{"key":"4572_CR60","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-21-564","author":"J Xu","year":"2021","unstructured":"Xu J, Wu W, Wu C, Mao Y, Qi X, Guo L, et al. A large-scale, multicentered trial evaluating the sensitivity and specificity of digital PCR versus ARMS-PCR for detecting ctDNA-based EGFR p.T790M in non-small-cell lung cancer patients. Transl Lung Cancer Res. 2021. https:\/\/doi.org\/10.21037\/tlcr-21-564.","journal-title":"Transl Lung Cancer Res"},{"key":"4572_CR61","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-42044-8_8","author":"E Trujillo-Arribas","year":"2016","unstructured":"Trujillo-Arribas E, Macher HC, Jim\u00e9nez-Arriscado P, de la Portilla F, Molinero P, Guerrero JM, et al. Screening of KRAS mutation in pre- and post-surgery serum of patients suffering from colon cancer by COLD-PCR HRM. Adv Exp Med Biol. 2016. https:\/\/doi.org\/10.1007\/978-3-319-42044-8_8.","journal-title":"Adv Exp Med Biol"},{"key":"4572_CR62","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13122040","author":"Y Kojima","year":"2023","unstructured":"Kojima Y, Noguchi E, Yoshino T, Yagishita S, Yazaki S, Okuma HS, et al. Development of a detection system for ESR1 mutations in circulating tumour DNA using PNA-LNA-mediated PCR clamping. Diagnostics (Basel). 2023. https:\/\/doi.org\/10.3390\/diagnostics13122040.","journal-title":"Diagnostics (Basel)"},{"issue":"16-17","key":"4572_CR63","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.clinbiochem.2014.08.015","volume":"47","author":"F Xie","year":"2014","unstructured":"Xie F, Huang J, Qu S, Wu W, Jiang J, Wang H, et al. Sensitive detection of trace amounts of KRAS codon 12 mutations by a fast and novel one-step technique. Clin Biochem. 2014;47(16\u201317):237\u201342. https:\/\/doi.org\/10.1016\/j.clinbiochem.2014.08.015.","journal-title":"Clin Biochem"},{"key":"4572_CR64","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.978","author":"W Wang","year":"2016","unstructured":"Wang W, Song Z, Zhang Y. A comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistance. Cancer Med. 2016. https:\/\/doi.org\/10.1002\/cam4.978.","journal-title":"Cancer Med"},{"key":"4572_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-85160-6","author":"D Mirikar","year":"2025","unstructured":"Mirikar D, Banerjee N, Prabhash K, Kaushal RK, Naronha V, Pramesh CS, et al. Comparative analysis of EGFR mutations in circulating tumor DNA and primary tumor tissues from lung cancer patients using BEAMing PCR. Sci Rep. 2025. https:\/\/doi.org\/10.1038\/s41598-025-85160-6.","journal-title":"Sci Rep"},{"key":"4572_CR66","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkw650","author":"C Song","year":"2016","unstructured":"Song C, Liu Y, Fontana R, Makrigiorgos A, Mamon H, Kulke MH, et al. Elimination of unaltered DNA in mixed clinical samples via nuclease-assisted minor-allele enrichment. Nucleic Acids Res. 2016. https:\/\/doi.org\/10.1093\/nar\/gkw650.","journal-title":"Nucleic Acids Res"},{"issue":"136","key":"4572_CR67","doi-asserted-by":"publisher","first-page":"136ra68","DOI":"10.1126\/scitranslmed.3003726","volume":"4","author":"T Forshew","year":"2012","unstructured":"Forshew T, Murtaza M, Parkinson C, Gale D, Tsui DWY, Kaper F, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med. 2012;4(136):136ra68. https:\/\/doi.org\/10.1126\/scitranslmed.3003726.","journal-title":"Sci Transl Med"},{"key":"4572_CR68","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.33.15_suppl.e22057","author":"V Plagnol","year":"2015","unstructured":"Plagnol V, Lawson A, Forshew T, Fahem A, Brenton J, Gale D, et al. Assessment of clinical applications of circulating tumor DNA using an enhanced TAm-Seq platform. J Clin Oncol. 2015. https:\/\/doi.org\/10.1200\/jco.2015.33.15_suppl.e22057.","journal-title":"J Clin Oncol"},{"key":"4572_CR69","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2022.40.17_suppl.lba100","author":"J Tie","year":"2022","unstructured":"Tie J, Cohen J, Lahouel K, Lo SN, Wang Y, Wong R, et al. Adjuvant chemotherapy guided by circulating tumor DNA analysis in stage II colon cancer: the randomized DYNAMIC trial. J Clin Oncol. 2022. https:\/\/doi.org\/10.1200\/jco.2022.40.17_suppl.lba100.","journal-title":"J Clin Oncol"},{"issue":"10","key":"4572_CR70","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0140712","volume":"10","author":"RB Lanman","year":"2015","unstructured":"Lanman RB, Mortimer SA, Zill OA, Sebisanovic D, Lopez R, Blau S, et al. Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA. PLoS ONE. 2015;10(10):e0140712. https:\/\/doi.org\/10.1371\/journal.pone.0140712.","journal-title":"PLoS ONE"},{"key":"4572_CR71","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006284","author":"NP Semenkovich","year":"2023","unstructured":"Semenkovich NP, Szymanski JJ, Earland N, Chauhan PS, Pellini B, Chaudhuri AA. Genomic approaches to cancer and minimal residual disease detection using circulating tumor DNA. J Immunother Cancer. 2023. https:\/\/doi.org\/10.1136\/jitc-2022-006284.","journal-title":"J Immunother Cancer"},{"issue":"4","key":"4572_CR72","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1158\/1078-0432.CCR-15-1627-T","volume":"22","author":"CP Paweletz","year":"2016","unstructured":"Paweletz CP, Sacher AG, Raymond CK, Alden RS, O\u2019Connell A, Mach SL, et al. Bias-corrected targeted next-generation sequencing for rapid, multiplexed detection of actionable alterations in cell-free DNA from advanced lung cancer patients. Clin Cancer Res. 2016;22(4):915\u201322. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1627-T.","journal-title":"Clin Cancer Res"},{"key":"4572_CR73","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-19-2150","author":"C Serrano","year":"2019","unstructured":"Serrano C, Leal A, Kuang Y, Morgan JA, Barysauskas CM, Phallen J, et al. Phase I study of rapid alternation of sunitinib and regorafenib for the treatment of tyrosine kinase inhibitor refractory gastrointestinal stromal tumors. Clin Cancer Res. 2019. https:\/\/doi.org\/10.1158\/1078-0432.ccr-19-2150.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"4572_CR74","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/s41551-021-00837-3","volume":"6","author":"P Song","year":"2022","unstructured":"Song P, Wu LR, Yan YH, Zhang JX, Chu T, Kwong LN, et al. Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics. Nat Biomed Eng. 2022;6(3):232\u201345. https:\/\/doi.org\/10.1038\/s41551-021-00837-3.","journal-title":"Nat Biomed Eng"},{"issue":"4","key":"4572_CR75","doi-asserted-by":"publisher","DOI":"10.1186\/gm439","volume":"5","author":"C Farris","year":"2013","unstructured":"Farris C, Trimarchi JM. Plasma-seq: a novel strategy for metastatic prostate cancer analysis. Genome Med. 2013;5(4):35. https:\/\/doi.org\/10.1186\/gm439.","journal-title":"Genome Med"},{"key":"4572_CR76","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31397","author":"J Belic","year":"2018","unstructured":"Belic J, Graf R, Bauernhofer T, Cherkas Y, Ulz P, Waldispuehl-Geigl J, et al. Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide. Int J Cancer. 2018. https:\/\/doi.org\/10.1002\/ijc.31397.","journal-title":"Int J Cancer"},{"issue":"162","key":"4572_CR77","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3004742","volume":"4","author":"RJ Leary","year":"2012","unstructured":"Leary RJ, Sausen M, Kinde I, Papadopoulos N, Carpten JD, Craig D, et al. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med. 2012;4(162):162ra54. https:\/\/doi.org\/10.1126\/scitranslmed.3004742.","journal-title":"Sci Transl Med"},{"key":"4572_CR78","doi-asserted-by":"publisher","DOI":"10.1002\/viw.20240145","author":"W Yu","year":"2025","unstructured":"Yu W, Canjun L, Tao Z, Jianyang W, Wenyang L, Lei D, et al. Circulating genomic biomarkers predict chemoradiotherapy resistance and immunotherapy response in locally advanced non-small-cell lung cancer. VIEW. 2025. https:\/\/doi.org\/10.1002\/viw.20240145.","journal-title":"VIEW"},{"key":"4572_CR79","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2014.234286","author":"J Belic","year":"2015","unstructured":"Belic J, Koch M, Ulz P, Auer M, Gerhalter T, Mohan S, et al. Rapid identification of plasma DNA samples with increased ctDNA levels by a modified FAST-SeqS approach. Clin Chem. 2015. https:\/\/doi.org\/10.1373\/clinchem.2014.234286.","journal-title":"Clin Chem"},{"issue":"6","key":"4572_CR80","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41551-021-00746-5","volume":"5","author":"N Liang","year":"2021","unstructured":"Liang N, Li B, Jia Z, Wang C, Wu P, Zheng T, et al. Ultrasensitive detection of circulating tumour DNA via deep methylation sequencing aided by machine learning. Nat Biomed Eng. 2021;5(6):586\u201399. https:\/\/doi.org\/10.1038\/s41551-021-00746-5.","journal-title":"Nat Biomed Eng"},{"issue":"4","key":"4572_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2025.101727","volume":"10","author":"ES Lebow","year":"2025","unstructured":"Lebow ES, Eichholz J, Boe L, Zhang Z, Kratochvil LB, Gelblum DY, et al. Cell-free circulating tumor DNA for noninvasive molecular profiling among patients undergoing definitive chemoradiation for locally advanced lung cancer. Adv Radiat Oncol. 2025;10(4):101727. https:\/\/doi.org\/10.1016\/j.adro.2025.101727.","journal-title":"Adv Radiat Oncol"},{"key":"4572_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2026.103992","author":"H Horndalsveen","year":"2026","unstructured":"Horndalsveen H, Haakensen VD, Madebo T, Gr\u00f8nberg BH, Halvorsen TO, Bjaan\u00e6s MM, et al. CtDNA-based MRD detection in stage III NSCLC treated with chemoradiotherapy and durvalumab. J Thorac Oncol. 2026. https:\/\/doi.org\/10.1016\/j.jtho.2026.103992.","journal-title":"J Thorac Oncol"},{"issue":"13","key":"4572_CR83","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202413125","volume":"12","author":"L Wu","year":"2025","unstructured":"Wu L, Zhang Z, Jiang C, Li L, Sun X, Bai M, et al. Integration of circulating tumor DNA and metabolic parameters on 18F-fludeoxyglucose positron emission tomography for outcome prediction in unresectable locally advanced non-small cell lung cancer. Adv Sci. 2025;12(13):e2413125. https:\/\/doi.org\/10.1002\/advs.202413125.","journal-title":"Adv Sci"},{"issue":"10","key":"4572_CR84","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/j.jtho.2024.06.024","volume":"19","author":"S Jun","year":"2024","unstructured":"Jun S, Shukla NA, Durm G, Hui AB, Cao S, Ganti AK, et al. Analysis of circulating tumor DNA predicts outcomes of short-course consolidation immunotherapy in unresectable stage III NSCLC. J Thorac Oncol. 2024;19(10):1427\u201337. https:\/\/doi.org\/10.1016\/j.jtho.2024.06.024.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"4572_CR85","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s43018-019-0011-0","volume":"1","author":"EJ Moding","year":"2020","unstructured":"Moding EJ, Liu Y, Nabet BY, Chabon JJ, Chaudhuri AA, Hui AB, et al. Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small cell lung cancer. Nat Cancer. 2020;1(2):176\u201383. https:\/\/doi.org\/10.1038\/s43018-019-0011-0.","journal-title":"Nat Cancer"},{"issue":"2","key":"4572_CR86","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jncc.2024.01.008","volume":"4","author":"Y Wang","year":"2024","unstructured":"Wang Y, Wang W, Zhang T, Yang Y, Wang J, Li C, et al. Dynamic bTMB combined with residual ctDNA improves survival prediction in locally advanced NSCLC patients with chemoradiotherapy and consolidation immunotherapy. J Natl Cancer Center. 2024;4(2):177\u201387. https:\/\/doi.org\/10.1016\/j.jncc.2024.01.008.","journal-title":"J Natl Cancer Center"},{"key":"4572_CR87","doi-asserted-by":"crossref","unstructured":"Reck M, Lee KH, Frost N, Breder VV, Kowalski DM, Levchenko E, et al. Four-year outcomes and circulating tumor DNA (ctDNA) analysis of pembrolizumab (pembro) plus concurrent chemoradiation therapy (cCRT) in unresectable, locally advanced, stage III non-small-cell lung cancer (NSCLC): from KEYNOTE-799. American Society of Clinical Oncology; 2024.","DOI":"10.1200\/JCO.2024.42.16_suppl.8057"},{"issue":"10","key":"4572_CR88","doi-asserted-by":"publisher","first-page":"S375","DOI":"10.1016\/j.jtho.2019.08.760","volume":"14","author":"J Jen","year":"2019","unstructured":"Jen J, Jang J, Zhang J, Tang A, Pierson K, Schrandt A, et al. P1. 01-45 A NGS-based ctDNA test to monitor disease progression and treatment response in advanced stage non-small cell lung cancer. J Thorac Oncol. 2019;14(10):S375.","journal-title":"J Thorac Oncol"},{"key":"4572_CR89","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2022.04.001","author":"C Marcus","year":"2022","unstructured":"Marcus C, Tajmir SH, Rowe SP, Sheikhbahaei S, Solnes LB. 18F-FDG PET\/CT for response assessment in lung cancer. Semin Nucl Med. 2022. https:\/\/doi.org\/10.1053\/j.semnuclmed.2022.04.001.","journal-title":"Semin Nucl Med"},{"key":"4572_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.08.013","author":"J Xu","year":"2024","unstructured":"Xu J, Wan R, Cai Y, Cai S, Wu L, Li B, et al. Circulating tumor DNA-based stratification strategy for chemotherapy plus PD-1 inhibitor in advanced non-small-cell lung cancer. Cancer Cell. 2024. https:\/\/doi.org\/10.1016\/j.ccell.2024.08.013.","journal-title":"Cancer Cell"},{"issue":"7","key":"4572_CR91","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/s41571-019-0202-8","volume":"16","author":"D Killock","year":"2019","unstructured":"Killock D. bTMB is a promising predictive biomarker. Nat Rev Clin Oncol. 2019;16(7):403. https:\/\/doi.org\/10.1038\/s41571-019-0202-8.","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"4572_CR92","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/s41591-022-01754-x","volume":"28","author":"ES Kim","year":"2022","unstructured":"Kim ES, Velcheti V, Mekhail T, Yun C, Shagan SM, Hu S, et al. Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial. Nat Med. 2022;28(5):939\u201345. https:\/\/doi.org\/10.1038\/s41591-022-01754-x.","journal-title":"Nat Med"},{"issue":"9","key":"4572_CR93","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1038\/s41591-022-01933-w","volume":"28","author":"S Peters","year":"2022","unstructured":"Peters S, Dziadziuszko R, Morabito A, Felip E, Gadgeel SM, Cheema P, et al. Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial. Nat Med. 2022;28(9):1831\u20139. https:\/\/doi.org\/10.1038\/s41591-022-01933-w.","journal-title":"Nat Med"},{"issue":"6","key":"4572_CR94","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1634\/theoncologist.2018-0433","volume":"24","author":"YK Chae","year":"2019","unstructured":"Chae YK, Davis AA, Agte S, Pan A, Simon NI, Iams WT, et al. Clinical implications of circulating tumor DNA tumor mutational burden (ctDNA TMB) in non-small cell lung cancer. Oncologist. 2019;24(6):820\u20138. https:\/\/doi.org\/10.1634\/theoncologist.2018-0433.","journal-title":"Oncologist"},{"key":"4572_CR95","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11113245","author":"YL Alfranca","year":"2022","unstructured":"Alfranca YL, Garcia MEO, Rueda AG, Ballesteros P\u00c1, Rodr\u00edguez DR, Velasco MT. Blood biomarkers of response to immune checkpoint inhibitors in non-small cell lung cancer. J Clin Med. 2022. https:\/\/doi.org\/10.3390\/jcm11113245.","journal-title":"J Clin Med"},{"key":"4572_CR96","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.108058","volume":"199","author":"A De Giglio","year":"2025","unstructured":"De Giglio A, De Biase D, Favorito V, Maloberti T, Di Federico A, Zacchini F, et al. STK11 mutations correlate with poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status. Lung Cancer. 2025;199:108058. https:\/\/doi.org\/10.1016\/j.lungcan.2024.108058.","journal-title":"Lung Cancer"},{"issue":"6","key":"4572_CR97","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.jtho.2024.03.002","volume":"19","author":"B Ricciuti","year":"2024","unstructured":"Ricciuti B, Garassino MC. Precision immunotherapy for STK11\/KEAP1-mutant NSCLC. J Thorac Oncol. 2024;19(6):877\u201382. https:\/\/doi.org\/10.1016\/j.jtho.2024.03.002.","journal-title":"J Thorac Oncol"},{"key":"4572_CR98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2019.09.005","volume":"137","author":"N Guibert","year":"2019","unstructured":"Guibert N, Jones G, Beeler JF, Plagnol V, Morris C, Mourlanette J, et al. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer. Lung Cancer. 2019;137:1\u20136. https:\/\/doi.org\/10.1016\/j.lungcan.2019.09.005.","journal-title":"Lung Cancer"},{"key":"4572_CR99","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1200\/PO.21.00182","volume":"5","author":"S Weber","year":"2021","unstructured":"Weber S, van der Leest P, Donker HC, Schlange T, Timens W, Tamminga M, et al. Dynamic changes of circulating tumor DNA predict clinical outcome in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitors. JCO Precis Oncol. 2021;5:1540\u201353. https:\/\/doi.org\/10.1200\/PO.21.00182.","journal-title":"JCO Precis Oncol"},{"issue":"3","key":"4572_CR100","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.21037\/tlcr-20-1118","volume":"10","author":"C Su","year":"2021","unstructured":"Su C, Wang X, Zhou J, Zhao J, Zhou F, Zhao G, et al. Titin mutation in circulatory tumor DNA is associated with efficacy to immune checkpoint blockade in advanced non-small cell lung cancer. Transl Lung Cancer Res. 2021;10(3):1256\u201365. https:\/\/doi.org\/10.21037\/tlcr-20-1118.","journal-title":"Transl Lung Cancer Res"},{"issue":"11","key":"4572_CR101","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1038\/s41591-022-02047-z","volume":"28","author":"J Jee","year":"2022","unstructured":"Jee J, Lebow ES, Yeh R, Das JP, Namakydoust A, Paik PK, et al. Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer. Nat Med. 2022;28(11):2353\u201363. https:\/\/doi.org\/10.1038\/s41591-022-02047-z.","journal-title":"Nat Med"},{"issue":"4","key":"4572_CR102","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1038\/s41591-023-02226-6","volume":"29","author":"ZJF Assaf","year":"2023","unstructured":"Assaf ZJF, Zou W, Fine AD, Socinski MA, Young A, Lipson D, et al. A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer. Nat Med. 2023;29(4):859\u201368. https:\/\/doi.org\/10.1038\/s41591-023-02226-6.","journal-title":"Nat Med"},{"issue":"9","key":"4572_CR103","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/ng1861","volume":"38","author":"SL Carter","year":"2006","unstructured":"Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet. 2006;38(9):1043\u20138.","journal-title":"Nat Genet"},{"issue":"1","key":"4572_CR104","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01331-9","volume":"20","author":"W Fang","year":"2021","unstructured":"Fang W, Jin H, Zhou H, Hong S, Ma Y, Zhang Y, et al. Intratumoral heterogeneity as a predictive biomarker in anti-PD-(L)1 therapies for non-small cell lung cancer. Mol Cancer. 2021;20(1):37. https:\/\/doi.org\/10.1186\/s12943-021-01331-9.","journal-title":"Mol Cancer"},{"issue":"1","key":"4572_CR105","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13046-025-03348-0","volume":"44","author":"F Janke","year":"2025","unstructured":"Janke F, Gasser M, Angeles AK, Riediger AL, G\u00f6rtz M, Appenheimer L, et al. Low-coverage whole genome sequencing of cell-free DNA to predict and track immunotherapy response in advanced non-small cell lung cancer. J Exp Clin Cancer Res. 2025;44(1):87. https:\/\/doi.org\/10.1186\/s13046-025-03348-0.","journal-title":"J Exp Clin Cancer Res"},{"key":"4572_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.09.001","author":"BY Nabet","year":"2020","unstructured":"Nabet BY, Esfahani MS, Moding EJ, Hamilton EG, Chabon JJ, Rizvi H, et al. Noninvasive early identification of therapeutic benefit from immune checkpoint inhibition. Cell. 2020. https:\/\/doi.org\/10.1016\/j.cell.2020.09.001.","journal-title":"Cell"},{"key":"4572_CR107","doi-asserted-by":"publisher","DOI":"10.1200\/po.23.00718","author":"H Ding","year":"2024","unstructured":"Ding H, Xu XS, Yang Y, Yuan M. Improving prediction of survival and progression in metastatic non-small cell lung cancer after immunotherapy through machine learning of circulating tumor DNA. JCO Precis Oncol. 2024. https:\/\/doi.org\/10.1200\/po.23.00718.","journal-title":"JCO Precis Oncol"},{"issue":"12","key":"4572_CR108","doi-asserted-by":"publisher","first-page":"8778","DOI":"10.21037\/tcr-2025-1182","volume":"14","author":"J Xia","year":"2025","unstructured":"Xia J, He T, Hu Y, Zhou D, Zou D, Li Y, et al. Development and validation of a circulating tumor DNA-based machine learning model for predicting immunotherapy response in non-small cell lung cancer. Transl Cancer Res. 2025;14(12):8778\u201391. https:\/\/doi.org\/10.21037\/tcr-2025-1182.","journal-title":"Transl Cancer Res"},{"issue":"24","key":"4572_CR109","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","volume":"379","author":"SJ Antonia","year":"2018","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379(24):2342\u201350. https:\/\/doi.org\/10.1056\/NEJMoa1809697.","journal-title":"N Engl J Med"},{"issue":"1","key":"4572_CR110","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","volume":"11","author":"P Goldstraw","year":"2016","unstructured":"Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WEE, et al. The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(1):39\u201351. https:\/\/doi.org\/10.1016\/j.jtho.2015.09.009.","journal-title":"J Thorac Oncol"},{"key":"4572_CR111","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216569","volume":"582","author":"Y Yang","year":"2024","unstructured":"Yang Y, Wang J, Wang J, Zhao X, Zhang T, Yang Y, et al. Unrevealing the therapeutic benefits of radiotherapy and consolidation immunotherapy using ctDNA-defined tumor clonality in unresectable locally advanced non-small cell lung cancer. Cancer Lett. 2024;582:216569. https:\/\/doi.org\/10.1016\/j.canlet.2023.216569.","journal-title":"Cancer Lett"},{"issue":"22","key":"4572_CR112","doi-asserted-by":"publisher","first-page":"4596","DOI":"10.1158\/1078-0432.CCR-23-1578","volume":"29","author":"B Pellini","year":"2023","unstructured":"Pellini B, Madison RW, Childress MA, Miller ST, Gjoerup O, Cheng J, et al. Circulating tumor DNA monitoring on chemo-immunotherapy for risk stratification in advanced non-small cell lung cancer. Clin Cancer Res. 2023;29(22):4596\u2013605. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1578.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"4572_CR113","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1158\/1078-0432.CCR-21-3074","volume":"28","author":"EC Nakajima","year":"2022","unstructured":"Nakajima EC, Drezner N, Li X, Mishra-Kalyani PS, Liu Y, Zhao H, et al. FDA approval summary: sotorasib for KRAS G12C-mutated metastatic NSCLC. Clin Cancer Res. 2022;28(8):1482\u20136. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3074.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"4572_CR114","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa2204619","volume":"387","author":"PA J\u00e4nne","year":"2022","unstructured":"J\u00e4nne PA, Riely GJ, Gadgeel SM, Heist RS, Ou S-HI, Pacheco JM, et al. Adagrasib in non-small-cell lung cancer harboring a KRASG12C mutation. N Engl J Med. 2022;387(2):120\u201331. https:\/\/doi.org\/10.1056\/NEJMoa2204619.","journal-title":"N Engl J Med"},{"issue":"7","key":"4572_CR115","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1001\/jamaoncol.2024.1779","volume":"10","author":"S Dong","year":"2024","unstructured":"Dong S, Wang Z, Zhang J-T, Yan B, Zhang C, Gao X, et al. Circulating tumor DNA-guided de-escalation targeted therapy for advanced non-small cell lung cancer: a nonrandomized controlled trial. JAMA Oncol. 2024;10(7):932\u201340. https:\/\/doi.org\/10.1001\/jamaoncol.2024.1779.","journal-title":"JAMA Oncol"},{"key":"4572_CR116","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.103109","volume":"155","author":"LS Pessoa","year":"2020","unstructured":"Pessoa LS, Heringer M, Ferrer VP. ctDNA as a cancer biomarker: a broad overview. Crit Rev Oncol Hematol. 2020;155:103109. https:\/\/doi.org\/10.1016\/j.critrevonc.2020.103109.","journal-title":"Crit Rev Oncol Hematol"},{"key":"4572_CR117","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13030551","author":"B Seliger","year":"2021","unstructured":"Seliger B, Massa C. Immune therapy resistance and immune escape of tumors. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13030551.","journal-title":"Cancers (Basel)"},{"key":"4572_CR118","doi-asserted-by":"publisher","DOI":"10.1200\/PO.21.00372","volume":"6","author":"DM Vega","year":"2022","unstructured":"Vega DM, Nishimura KK, Zariffa N, Thompson JC, Hoering A, Cilento V, et al. Changes in circulating tumor DNA reflect clinical benefit across multiple studies of patients with non-small-cell lung cancer treated with immune checkpoint inhibitors. JCO Precis Oncol. 2022;6:e2100372. https:\/\/doi.org\/10.1200\/PO.21.00372.","journal-title":"JCO Precis Oncol"},{"issue":"6","key":"4572_CR119","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1158\/0008-5472.CAN-18-1127","volume":"79","author":"V Anagnostou","year":"2019","unstructured":"Anagnostou V, Forde PM, White JR, Niknafs N, Hruban C, Naidoo J, et al. Dynamics of tumor and immune responses during immune checkpoint blockade in non-small cell lung cancer. Cancer Res. 2019;79(6):1214\u201325. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-1127.","journal-title":"Cancer Res"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04572-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04572-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04572-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:26:23Z","timestamp":1790573183000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04572-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":119,"alternative-id":["4572"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04572-6","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"29 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}